Aidence was founded in Amsterdam in 2015 by Mark-Jan Harte (CEO) and Jeroen van Duffelen (COO). Since then, the company has made waves in the medical imaging industry with its AI solution, Veye Chest. Lung cancer is one of the most common cancers worldwide and early detection is of great importance for survival. Aidence’s AI-enabled pulmonary nodule management assistant, Veye Chest, connects with existing imaging infrastructure and enables radiologists to better spot and track changes in pulmonary nodules.

Our partner icometrix have worked for a number of years with deep learning within diagnostics and treatment of some of the world’s most difficult and expensive neurological diseases: Multiple Sclerosis, Dementia, Alzheimer’s Disease, Brain Trauma and (soon available) Epilepsy. The solutions are fully approved by both American Food and Drug Administration (FDA) as well as CE-marked under the EU Medical Device Directory (MDD).

Qure.ai was founded in 2016. Our mission is to use artificial intelligence to make healthcare more accessible and affordable. Our core team combines deep learning expertise with clinical, scientific and regulatory knowledge. Our advisory panel consists of radiologists, other doctors and public health experts. We work with these specialists to define clinically relevant problems and design real-world solutions.